Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.
- Haggag, A.
- Roula, D.
- Bak, B. A.
- Fita, E. G.
- Nielsen, A. M.
- Demir, TEVFİK
- Astamirova, K.
- Philis-Tsimikas, A.
- Gupta, Y.
DOIAbstract
Aims: To confirm non-inferiority of insulin degludec/insulin aspart (IDegAsp) once-daily (OD) versus insulin glargine (IGlar) U100 OD + insulin aspart (IAsp) OD for HbA(1c) after 26 weeks, and compare efficacy and safety between groups at W26 + W38
Add to ORKG